What's new
This page lists items that we have published for the first time or updated in the last 7, 30 or 60 days. Use the filters to narrow results by audience, product type, content type or topic.
You can also stay informed by:
- subscribing to our updates to receive same-day notification emails on safety information, scheduling updates or media releases.
- checking our consultation hub.
- joining any upcoming events.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (12)
- Clinical trials (1)
- Committees and advisory bodies (2)
- Compliance and enforcement (13)
- Cosmetics (2)
- Fees and payments (3)
- Import and export (4)
- Labelling and packaging (2)
- Legislation (3)
- Manufacturing (8)
- Medicinal cannabis hub (2)
- Safety monitoring and information (17)
- Scheduling (national classification system) (5)
- Shortages and supply disruptions (9)
- Unique Device Identification (UDI) hub (3)
- Vaping hub (3)
What's new
127 result(s) found, displaying 1 to 25
-
ConsultationWe are seeking feedback on proposed changes to improve the Therapeutic Goods Advertising Code.
-
ConsultationWe are seeking feedback on the regulation of radiopharmaceuticals in Australia. These medicines contain small amounts of radioactive material, used to support the diagnosis and treatment of serious conditions, including cancer and cardiovascular disease.
-
ConsultationWe are seeking public comment on issues and proposed amendments to the Permissible Indications Determination.
-
News articlesFollowing a public consultation process between 24 November 2025 – 10 February 2026, the TGA has adopted 23 international scientific guidelines
-
DatasetSearch approvals to import and supply medicines not in the Australian Register of Therapeutic Goods (ARTG) to address medicine shortages.
-
PageThe Freedom of Information disclosure log gives access to information we've released in response to an FOI request.
-
Safety alertsProduct warnings across the GLP-1 RA class of medicines have been updated due to the potential for these products to cause a rare, but severe, form of eye disorder.
-
Safety updatesProduct warnings across the glucagon-like-peptide-1 receptor agonist (GLP-1 RA) class of medicines have been updated due to the potential for these products to cause a rare, but severe, form of eye disorder.
-
Regulatory decision noticesWe have added our recent decisions to the list of Australian manufacturers licensed by the TGA.
-
Australian public assessment report (AusPar)Tzield is indicated to delay the onset of Stage 3 type 1 diabetes mellitus (T1D) in adult and paediatric patients aged 8 years and older with Stage 2 type 1 diabetes mellitus.
-
PageView published decisions relating to the granting of licences for the manufacture of therapeutic goods in Australia.
-
Australian public assessment report (AusPar)Redemplo (plozasiran sodium) has been approved as an adjunct to diet to reduce triglyceride levels for adult patients with familial chylomicronaemia syndrome (FCS) for whom standard triglyceride lowering therapies have been inadequate.
-
PageView published decisions relating to the revocation of licences for the manufacture therapeutic goods in Australia.
-
PageView published decisions relating to the suspension of licences for the manufacture of therapeutic goods in Australia.
-
PageFind out answers to frequently asked questions about advertising cosmetic injection services and our guidelines.
-
PageUnderstand our requirements for advertising price lists for therapeutic goods that are prohibited from advertising to consumers. Relates to Part 9 of the Advertising Code.
-
GuidanceGuidance about how to advertise therapeutic goods exclusively to health professionals.
-
GuidanceThis Guidance explains part 9 of the Code, which has requirements about advertising the price of prescription medicines and certain pharmacist-only medicines to the public.
-
User guideA guide for using the TGA Business services (TBS) portal for listed and assessed listed medicine applications.
-
Scheduling submissionsFind out about the public submissions on scheduling matters referred to the ACMS #47 meeting held in June 2025
-
Prescription medicine decision summaryALTUVIIIO (efanesoctocog alfa) is approved for adults, adolescents and children with haemophilia A.
-
Meeting statementsCommunique from the 6th meeting of the Human Research Ethics Committee and TGA Clinical Trials Discussion Forum, 14 July 2026.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Australian public assessment report (AusPar)Slenyto (Melatonin) is approved to treat insomnia in children and adolescents with ASD, certain neurogenetic disorders (ages 2-18), or ADHD (ages 6-17) when sleep hygiene measures alone have not been effective.
-
Prescription medicine decision summarySodium Oxybate-Reach has been approved for the treatment of narcolepsy in adults, adolescents and children from the age of 7 years.